|
1
|
Einhorn LH: Curing metastatic testicular
cancer. Proc Natl Acad Sci USA. 99:4592–4595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karasawa T and Steyger PS: An integrated
view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol
Lett. 237:219–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brock PR, Knight KR, Freyer DR, Campbell
KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput
K, et al: Platinum-induced ototoxicity in children: A consensus
review on mechanisms, predisposition, and protection, including a
new International Society of Pediatric Oncology Boston ototoxicity
scale. J Clin Oncol. 30:2408–2417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McWhinney SR, Goldberg RM and McLeod HL:
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 8:10–16.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yao X, Panichpisal K, Kurtzman N and
Nugent K: Cisplatin nephrotoxicity: A review. Am J Med Sci.
334:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nozaki Y, Kinoshita K, Hino S, Yano T,
Niki K, Hirooka Y, Kishimoto K, Funauchi M and Matsumura I:
Signaling Rho-kinase mediates inflammation and apoptosis in T cells
and renal tubules in cisplatin nephrotoxicity. Am J Physiol Renal
Physiol. 308:F899–F909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hagar H, Medany AE, Salam R, Medany GE and
Nayal OA: Betaine supplementation mitigates cisplatin-induced
nephrotoxicity by abrogation of oxidative/nitrosative stress and
suppression of inflammation and apoptosis in rats. Exp Toxicol
Pathol. 67:133–141. 2015. View Article : Google Scholar
|
|
9
|
Chen Q, Peng H, Dong L, Chen L, Ma X, Peng
Y, Dai S and Liu Q: Activation of the NRF2-ARE signalling pathway
by the Lentinula edodes polysaccharose LNT alleviates ROS-mediated
cisplatin nephrotoxicity. Int Immunopharmacol. 36:1–8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma X, Dang C, Kang H, Dai Z, Lin S, Guan
H, Liu X, Wang X and Hui W: Saikosaponin-D reduces
cisplatin-induced nephrotoxicity by repressing ROS-mediated
activation of MAPK and NF-κB signalling pathways. Int
Immunopharmacol. 28:399–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Francescato HD, Costa RS, Silva CG and
Coimbra TM: Treatment with a p38 MAPK inhibitor attenuates
cisplatin nephrotoxicity starting after the beginning of renal
damage. Life Sci. 84:590–597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mishima K, Baba A, Matsuo M, Itoh Y and
Oishi R: Protective effect of cyclic AMP against cisplatin-induced
nephrotoxicity. Free Radic Biol Med. 40:1564–1577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramesh G and Reeves WB: p38 MAP kinase
inhibition ameliorates cisplatin nephrotoxicity in mice. Am J
Physiol Renal Physiol. 289:F166–F174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao Y, Le K, Cheng H and Aplin AE: NF-κB
regulation of c-FLIP promotes TNFα-mediated RAF inhibitor
resistance in melanoma. J Invest Dermatol. 135:1839–1848. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsubaki M, Ogawa N, Takeda T, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Satou T and Nishida S:
Dimethyl fumarate induces apoptosis of hematopoietic tumor cells
via inhibition of NF-κB nuclear translocation and down-regulation
of Bcl-xL and XIAP. Biomed Pharmacother. 68:999–1005. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang T, Lan J, Huang Q, Chen X, Sun X, Liu
X, Yang P, Jin T, Wang S and Mou X: Embelin sensitizes acute
myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB
inactivation. Cell Biochem Biophys. 71:291–297. 2015. View Article : Google Scholar
|
|
17
|
Hughes MA, Powley IR, Jukes-Jones R, Horn
S, Feoktistova M, Fairall L, Schwabe JW, Leverkus M, Cain K and
MacFarlane M: Co-operative and hierarchical binding of c-flip and
caspase-8: A unified model defines how c-flip isoforms
differentially control cell fate. Mol Cell. 61:834–849. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elsawy MA, Martin L, Tikhonova IG and
Walker B: Solid phase synthesis of Smac/DIABLO-derived peptides
using a ‘Safety-Catch’ resin: Identification of potent XIAP BIR3
antagonists. Bioorg Med Chem. 21:5004–5011. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwan HY, Niu X, Dai W, Tong T, Chao X, Su
T, Chan CL, Lee KC, Fu X, Yi H, et al: Lipidomic-based
investigation into the regulatory effect of schisandrin B on
palmitic acid level in non-alcoholic steatotic livers. Sci Rep.
5:91142015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pao TT, Hsu KF, Liu KT, Chang LG, Chuang
CH and Sung CY: Protective action of schizandrin B on hepatic
injury in mice. Chin Med J. 3:173–179. 1977.PubMed/NCBI
|
|
21
|
Yang T, Liu S, Zheng TH, Tao YY and Liu
CH: Comparative pharmacokinetics and tissue distribution profiles
of lignan components in normal and hepatic fibrosis rats after oral
administration of Fuzheng Huayu recipe. J Ethnopharmacol.
166:305–312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang EP, Li H, Yu CR, Yu CY, Jing S, Sun
HX, Wang CM, Fan XT, Chen JG and Wang S: Schisandrin B protects
PC12 cells against oxidative stress of neurodegenerative diseases.
Neuroreport. 26:360–366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stacchiotti A, Li Volti G, Lavazza A,
Schena I, Aleo MF, Rodella LF and Rezzani R: Different role of
schisandrin B on mercury-induced renal damage in vivo and in vitro.
Toxicology. 286:48–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thandavarayan RA, Giridharan VV, Arumugam
S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K and Konishi T:
Schisandrin B prevents doxorubicin induced cardiac dysfunction by
modulation of DNA damage, oxidative stress and inflammation through
inhibition of MAPK/p53 signaling. PLoS One. 10:e01192142015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiu PY, Leung HY, Poon MK, Mak DH and Ko
KM: (−) Schisandrin B is more potent than its enantiomer in
enhancing cellular glutathione and heat shock protein production as
well as protecting against oxidant injury in H9c2 cardiomyocytes.
Mol Cell Biochem. 289:185–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv XJ, Zhao LJ, Hao YQ, Su ZZ, Li JY, Du
YW and Zhang J: Schisandrin B inhibits the proliferation of human
lung adenocarcinoma A549 cells by inducing cycle arrest and
apoptosis. Int J Clini Exp Med. 8:6926–6936. 2015.
|
|
27
|
Bunel V, Antoine MH, Nortier J, Duez P and
Stévigny C: Protective effects of schizandrin and schizandrin B
towards cisplatin nephrotoxicity in vitro. J Appl Toxicol.
34:1311–1319. 2014. View
Article : Google Scholar
|
|
28
|
Fernandes-Alnemri T, Litwack G and Alnemri
ES: CPP32, a novel human apoptotic protein with homology to
Caenorhabditis elegans cell death protein Ced-3 and mammalian
interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764.
1994.PubMed/NCBI
|
|
29
|
Reed JC and Reed SI: Survivin’
cell-separation anxiety:. Nat Cell Biol. 1:E199–E200. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li F, Ackermann EJ, Bennett CF, Rothermel
AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC:
Pleiotropic cell-division defects and apoptosis induced by
interference with survivin function. Nat Cell Biol. 1:461–466.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dong Q, Hou H, Wu J and Chen Y: The
Nrf2-ARE pathway is associated with Schisandrin B attenuating
benzo(a) pyrene-Induced HTR cells damages in vitro. Environ
Toxicol. 31:1439–1449. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Filipski KK, Mathijssen RH, Mikkelsen TS,
Schinkel AH and Sparreboom A: Contribution of organic cation
transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin
Pharmacol Ther. 86:396–402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pabla N, Murphy RF, Liu K and Dong Z: The
copper transporter Ctr1 contributes to cisplatin uptake by renal
tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal
Physiol. 296:F505–F511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Juo P, Kuo CJ, Yuan J and Blenis J:
Essential requirement for caspase-8/FLICE in the initiation of the
Fas-induced apoptotic cascade. Curr Biol. 8:1001–1008. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu H and Baliga R: Endoplasmic reticulum
stress-associated caspase 12 mediates cisplatin-induced LLC-PK1
cell apoptosis. J Am Soc Nephrol. 16:1985–1992. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Omar HA, Mohamed WR, Arab HH and Arafa
el-SA: Tangeretin alleviates cisplatin-induced acute hepatic injury
in rats: Targeting MAPKs and apoptosis. PLoS One. 11:e01516492016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsumoto M, Nakajima W, Seike M, Gemma A
and Tanaka N: Cisplatin-induced apoptosis in non-small-cell lung
cancer cells is dependent on Bax- and Bak-induction pathway and
synergistically activated by BH3-mimetic ABT-263 in p53 wild-type
and mutant cells. Biochem Biophys Res Commun. 473:490–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
O’Connor DS, Grossman D, Plescia J, Li F,
Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation
of apoptosis at cell division by p34cdc2 phosphorylation of
survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000. View Article : Google Scholar
|
|
39
|
Perkins ND: Post-translational
modifications regulating the activity and function of the nuclear
factor kappa B pathway. Oncogene. 25:6717–6730. 2006. View Article : Google Scholar : PubMed/NCBI
|
